Improving SFC Chiral Separations by Employing a New Chlorinated Polysaccharide Chiral Stationary Phase: The RegisPack CLA-1
The Application Notebook
As the number of chiral columns and chiral separations has grown, it has become difficult to organize the information for use in developing new methods. The success of chiral method development depends on the introduction of appropriate columns. The RegisPack? polysaccharide-based chiral stationary phase (CSP) is most successful in achieving a majority of chiral separations. However, there are cases in which this proven chiral selector leads to partial or no separation. Excellent separations using the newly introduced RegisPack? CLA-1 CSP have been obtained for a range of compounds, either by improving or complementing RegisPack's selectivity.
As the number of chiral columns and chiral separations has grown, it has become difficult to organize the information for use in developing new methods. The success of chiral method development depends on the introduction of appropriate columns. The RegisPack® polysaccharide-based chiral stationary phase (CSP) is most successful in achieving a majority of chiral separations. However, there are cases in which this proven chiral selector leads to partial or no separation. Excellent separations using the newly introduced RegisPack® CLA-1 CSP have been obtained for a range of compounds, either by improving or complementing RegisPack's selectivity.
This study used the well-established RegisPack® CSP and the new chlorinated RegisPack® CLA-1 CSP. Both phases were based on 5-µm silica. Columns were both 25 cm x 4.6 mm in size.
Figure 1: Chromatogram Set 1. Sample: Propafenone. Mobile Phase: CO2/IPA (70/30) + 0.5% DEA. Flow Rate: 4.0 mL/min. Temp: 40 °C. Pressure: 125 bar. UV: 254 nm.
The RegisPack® and RegisPack® CLA-1 are coated with tris-(3,5-dimethylphenyl) carbamate of amylose and tris-(5-chloro-2-methylphenyl) carbamate of amylose, respectively.
Table I: Various other samples screened showing an improvement in separation with RegisPack® CLA-1.
This study investigated several compounds that had poor or no separation on a RegisPack® column. They were screened on the new RegisPack® CLA-1 column. Following are some chromatographic illustrations and a tabular summary of our results.
Figure 2: Chromatogram Set 2. Sample: Verapamil. Mobile Phase: CO2/IPA (75/25) + 0.5% DEA. Flow Rate: 4.0 mL/min. Temp: 40 °C. Pressure: 125 bar. UV: 290 nm.
Conclusion
The RegisPack® is a well-established CSP that does a superior job of separating the majority of compounds submitted for chiral screening. There are cases where the RegisPack® CSP can only achieve partial or no separation on some analytes. The new RegisPack® CLA-1 can exhibit unique selectivity in separation when existing CSP's fail. This CSP is highly recommended to be added to the screening process.
Note
All work was performed on a WATERS THAR SFC Method Station.
Regis Technologies, Inc.
8210 Austin Ave, Morton Grove, IL 60053
tel. (847) 583-7661, fax (847) 967-1214
E-mail: teds@registech.com, Website: www.registech.com/chiral
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.
